Remove 2027 Remove Disease Remove Trials
article thumbnail

The Biotech Startup Contraction Continues… And That’s A Good Thing

LifeSciVC

Further, this lemming challenge has also moved well beyond oncology – think of all the “not-so-fast follower” autoimmune programs or metabolic disease stories. Further, the competitive intensity in certain areas makes the “clinical do-ability” too challenging, even if those drugs could likely be beneficial.

DNA 112
article thumbnail

Amgen Named To Dow Jones Sustainability World Index For Eighth Consecutive Year

The Pharma Data

.” Amgen’s four ESG pillars – Healthy People, Healthy Society, Healthy Environment and a Healthy Amgen – include commitments to: Achieve carbon neutrality by 2027, along with a 40% reduction in water used and a 75% reduction in waste disposed.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

AI-Designed Drugs vs. Traditional Drug Discovery: Pros and Cons

Vial

billion by 2027 , at a compound annual growth rate (CAGR) of 45.7% As a result of this shorter timeline, AI-designed drugs also offer the potential to reduce the cost of drug discovery because the traditional process of drug discovery typically involves expensive and time-consuming clinical trials to evaluate promising compounds.

Drugs 52
article thumbnail

AMGEN RECOGNIZED FOR OUTSTANDING ESG PERFORMANCE

The Pharma Data

.” Amgen’s four ESG pillars – Healthy People, Healthy Society, Healthy Planet, and a Healthy Amgen – include commitments to: Achieve carbon neutrality by 2027, along with a 40% reduction in water used and a 75% reduction in waste disposed.

article thumbnail

BridgeBio Pharma, Inc. Prices Upsized Offering of $650 Million Convertible Senior Notes

The Pharma Data

This activity could increase (or reduce the size of any decrease in) the market price of the Company’s common stock, the notes or the Company’s 2.50% Convertible Senior Notes due 2027 at that time. BridgeBio’s pipeline of over 20 development programs includes product candidates ranging from early discovery to late-stage development.

article thumbnail

Article FDA Thank You Diagnostics landscape analysis: Key issues and a look ahead at 2024

Agency IQ

BY LAURA DIANGELO, MPH | JAN 30, 2024 10:25 AM CST Diagnostic regulation: A quick overview Diagnostics products are those intended to identify, signal or detect a specific health condition, infection or disease, or monitor a person’s health or health status. In-house tests (similar to LDTs in the U.S.,

FDA 40
article thumbnail

Article FDA Thank You Top questions on FDA’s proposed LDT rule: Carve outs, capacity and quality systems

Agency IQ

This has allowed them instead to be developed and run primarily under oversight from other agencies – including the Centers for Disease Control and Prevention (CDC) and Center for Medicare and Medicaid Services (CMS) – under a policy known as the Clinical Laboratory Improvement Amendments (CLIA). A trial run: The Covid-19 EUA transition.

FDA 40